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Abstract
Background: Setting priorities for the funding of new anti-cancer agents is becoming increasingly
complex. The funding of adjuvant trastuzumab for breast cancer has brought this dilemma to the
fore. In this paper we review external factors that may influence decision-making bodies and
present a case study of media response in Ontario, Canada to adjuvant trastuzumab for breast
cancer.
Methods: A comprehensive search of the databases of Canadian national and local newspapers
and television was performed. Articles pertaining to trastuzumab in adjuvant breast cancer as well
as 17 other anti-cancer drugs and indications were retrieved. The search period was from the date
when individual trial results were announced to the date funding was made available in Ontario.
Results:  During the 2.6 months between the release of the trastuzumab results to funding
approval in Ontario, we identified 51 episodes of media coverage. For the 17 other drugs/
indications (7 breast and 10 non-breast), the median time to funding approval was 31 months (range
14–46). Other recent major advances in oncology such as adjuvant vinorelbine/cisplatin for
resected NSCLC and docetaxel for advanced prostate cancer received considerably less media
attention (17 media reports for each) than trastuzumab. The median number of media reports for
breast cancer drugs was 4.5 compared to 2.5 for non-breast cancer drugs (p = 0.56).
Conclusion: Priority-setting for novel anti-cancer agents is a complex process that tries to ensure
fair use of constrained resources to fund therapies with the best evidence of clinical benefit.
However, this process is subject to external factors including the influence of media, patient
advocates, politicians, and industry. The data in this case study serve to illustrate the significant
involvement one (or all) of these external factors may play in the debate over priority-setting.
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Background
With the number and cost of new anti-cancer drugs rising
dramatically, setting priorities for funding these therapies
is becoming increasingly complex in private and public
health care systems worldwide. The role of trastuzumab in
the adjuvant management of breast cancer has brought
this dilemma to the fore.
Criteria for establishing a legitimate and fair process for
priority-setting have been proposed by Daniels and
include: "...transparency about the grounds for decisions;
appeals to rationales that all can accept as relevant to
meeting health needs fairly; and procedures for revising
decisions in light of challenges to them." [1].
Two studies have specifically evaluated the process of
rationing new anti-cancer therapies. In their review of
decision-making at Christie Hospital NHS Trust (UK), Foy
et al described that funding decisions were based largely
on evidence thresholds which were cut-off points deter-
mined from information on effectiveness [2]. In a study of
priority-setting decisions for new cancer drugs in Ontario,
Canada Martin and colleagues reported that although
clinical benefit was the primary factor in decision-making,
rationales could change with changing costs and/or budg-
ets [3]. Common to both of these studies was the finding
that external factors including pressure from political,
social and physician groups had some role in decision-
making.
Media coverage of health is recognized as one external fac-
tor which may influence the delivery of health care. A
recent Cochrane Library overview found that mass media
information on health-related issues may induce changes
in health services utilization, both through planned cam-
paigns and unplanned coverage [4]. The manner in which
the media portray an issue can have significant implica-
tions on the public's participation in rationing of health
care resources. This was seen in the media coverage of the
Child B case in the UK when a young child was denied
funding for further chemotherapy and a second bone
marrow transplant for advanced leukemia. Data from this
controversy depicted how different media outlets can por-
tray the same story in vastly different lights [5].
The recent process of approving funds for adjuvant trastu-
zumab in breast cancer in Ontario and the UK has high-
lighted the need for a legitimate and fair approach to
priority-setting. It has also brought to the forefront the
potential influence of external factors such as patient
groups, politicians, the media, and industry. In a recent
commentary piece Ferner and McDowell [6] described
how several factors may influence the National Institute
of Health and Clinical Excellence (NICE) in its appraisal
of the evidence for adjuvant trastuzumab in breast cancer.
The potential for such external factors to interact with
each other and with proposed domains of priority-setting
[7] are shown in Figure 1.
While external factors are recognized as having potential
to influence priority-setting, there is a paucity of data
describing specific examples of how such factors can man-
ifest in the rationing of anti-cancer therapy. In this paper
we present a case study which contrasts the Ontario
media's response to adjuvant trastuzumab with other
anti-cancer agents to provide a detailed example of how
one of these external factors (i.e. media coverage) may
influence decision-making bodies. For comparative pur-
poses we also evaluated the degree of media interest for 17
other novel anti-cancer agents and indications. The sec-
ond objective of this study was to describe time to funding
for each of these anti-cancer agents.
Methods
Case study: process of drug funding in Ontario
The province of Ontario has a "Committee to Evaluate
Drugs" (CED) that provides specialized advice to the Min-
istry of Health and Long-Term Care on which therapies
should be funded by the publicly funded drug program in
Ontario. In 2005, an expert sub-committee of the CED
was created in which members of the CED and represent-
atives from Cancer Care Ontario (CCO – the provincial
body that coordinates cancer care) consider which new
cancer medications will be funded in Ontario. The CED-
CCO sub-committee considers rigorously developed evi-
dence-based guidelines from the CCO program in evi-
dence-based care, pharmacoeconomic data, and other
relevant information before making a funding recom-
mendation to the CED. The CED reviews this recommen-
dation and makes a final recommendation on funding to
the Ministry of Health and Long-Term Care. This process
ensures that cancer drugs are considered through a review
mechanism that is consistent with the process used to
make funding decisions for other provincially funded
medications. The CED-CCO sub-committee has some
major differences from the decision-making body it
replaced (the CCO Policy Advisory Committee) in that its
deliberations are now confidential and economic analyses
are now a major component of the decision-making proc-
ess.
Case study: funding of adjuvant trastuzumab in Ontario
All four randomized trials of trastuzumab in early stage
HER-2 positive breast cancer have demonstrated signifi-
cant benefits for treatment with trastuzumab [8-10].
These data show a 50% relative risk reduction in breast
cancer recurrence, that occurs regardless of when (concur-
rent versus sequential with chemotherapy) or to which
type of chemotherapy regimen trastuzumab is added.
More recent analyses have also demonstrated actual sur-BMC Cancer 2007, 7:110 http://www.biomedcentral.com/1471-2407/7/110
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vival benefits [11]. Following the initial presentation of
the results of three of these trials [12,13] at the American
Society of Clinical Oncology (ASCO) annual meeting on
May 16, 2005, there was a massive call from oncologists,
patients and support groups alike for rapid access to the
drug. In Ontario, trastuzumab was approved for use in
early stage breast cancer at an unprecedented rate; funding
approval was granted within 67 days of the ASCO presen-
tation.
Media database search and analysis
Time to funding approval was calculated for trastuzumab
and a comparison cohort of other anti-cancer agents and
indications. The comparison cohort comprised all thera-
pies which had been submitted to Cancer Care Ontario
for consideration of funding since 2000 (n = 17). Time to
funding was defined as the number of months which
elapsed from the release of initial study results, until the
date that funding was made available in Ontario. The
search was censored at August 1st 2005 (the start date of
funding for adjuvant trastuzumab). For drugs in which a
decision had not yet been reached, we report the amount
of time from release of results until August 1st 2005.
A comprehensive search of the Toronto Public Library
database was undertaken for episodes of media coverage
related to each of the 18 therapeutics and indications. The
search period for the media database portion of this study
was defined as described for the time to funding calcula-
tion. The database includes articles from Canada's two
national newspapers and major newspapers from all cities
across Ontario with populations of ≥ 250,000. Broadcast
news reports (television and radio) were identified using
databases for the major Canadian televised news networks
and FP INFOMART. The newswire website was searched
for releases by Canadian Press. The final data were pre-
sented descriptively as means, medians and proportions.
Spearman's rho was used to calculate the correlation
between intensity of media coverage and time to drug
funding approval. The non-parametric Mann Whitney U-
test was used to compare the number of media reports for
breast cancer drugs to non-breast cancer drugs. All of the
statistical analyses were performed using Stata, release 9.0
(Stata Corp., College Station, Texas, USA).
Results
Time to funding
The first interim analyses of three adjuvant trastuzumab
studies were presented at a late- breaking session at the
ASCO meeting on May 16, 2005 [12,13]. On July 22 (67
days later), trastuzumab for early stage breast cancer
received approval for funding in the province of Ontario.
Funding was made available 10 days later on August 1
2005. The peer reviewed publications were not published
until October 20 2005, a further 81 days later [8,9].
Table 1 presents the time to funding decision as of August
1 2005 for 18 intravenous and oral anti-cancer agents and
indications in Ontario. While funding for trastuzumab
was made available within 3 months of release of study
results, the median time to funding for 17 other drugs was
31 months (range 14–46). At the time of data censoring
(August 1st 2005), a funding decision had still not been
made for 9 of these 17 indications.
Media coverage
During the 76 days between the announcement of trastu-
zumab results and funding becoming available, we iden-
tified a total of 51 episodes of media coverage; 27
newspaper, 9 television, 1 radio and 14 Canadian Press
items (Figure 2). The frequency of reports followed an
upward trend as the weeks passed reaching a maximum
on week 9. This coincided with the provincial government
announcing approval for trastuzumab for early stage
breast cancer (Figure 3).
As shown in Figure 2 there was considerably less media
attention for other drugs and indications. After trastuzu-
mab (n = 51) the drug with the most media coverage was
Potential interaction between external factors (shown in red)  and the domains of priority-setting (shown in blue) Figure 1
Potential interaction between external factors (shown in red) 
and the domains of priority-setting (shown in blue).
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anastrozole for adjuvant therapy of breast cancer (n = 33).
However with the latter, the 33 media reports were over
39 months translating approximately 1.2 reports com-
pared to 17 reports per month for trastuzumab (Table 1).
Other recent major advances in oncology such as adjuvant
vinorelbine/cisplatin for resected non-small cell lung can-
cer (NSCLC) [27] and docetaxel for advanced prostate
cancer [30] received considerably less media attention (17
media reports for each) than trastuzumab. Overall, there
was a negative correlation where increased media cover-
age was associated with a reduced time to drug funding
approval. (Spearman's rho r = 0.30, p = 0.23, 95%CI: -.84
to 0.23). The median number of media reports for breast
cancer drugs (n = 8) was 4.5 compared to 2.5 for non-
breast cancer drugs (n = 10) (p = 0.56).
Discussion and conclusion
In Ontario, the review process for trastuzumab was fast-
tracked, meaning that the drug was recommended several
months sooner than would normally have been the case.
"Our goal is always to get all Ontarians better access to the
effective medications and treatments they need," said the
Minister for Health and Long-Term Care George Smither-
man. "With Herceptin, we were able to speed up, but not
compromise, the extremely important review process"
[31]. This press release occurred at the tail-end of 9 weeks
of mounting media and public pressure. While this was
excellent news for breast cancer patients, it raises concern
about the speed of funding approval for other agents and
indications.
In this report we focus on the potential for media to influ-
ence drug funding decisions. Other factors (politics,
patient advocacy groups, and industry) have also been
implicated in other (non-cancer) drug approval processes.
In their review of drug approval time at the United States
Food and Drug Administration (FDA), Carpenter and
Fendrick found that the time to drug approval was related
to staffing levels at the FDA and disease politics (including
media coverage and wealth of patient advocacy groups)
[32]. The decision of the FDA to postpone the switch of
emergency contraception (Plan B) to over-the-counter sta-
tus was widely attributed to political interference [33].
Finally, it has been suggested that political factors contrib-
uted to the "chaos and conflict" surrounding the introduc-
tion of adjuvant trastuzumab in UK [34,35]. As depicted
in Figure 1 it is unlikely that these external factors operate
in isolation; there are likely interdependent relationships
between media, politics, industry and patient advocacy,
which together may influence drug funding decision-
making.
One may expect that speed of drug funding decisions be
influenced by the magnitude of clinical effect, the number
of patients who could benefit from the treatment, and
whether the treatment was curative or palliative. Accord-
ingly, it would not be surprising if a drug for a rare disease
with only a small magnitude of benefit in the palliative
setting was not funded rapidly, if at all. Clearly this was
not the case with trastuzumab which has an impressive
18% absolute increase in 4 year DFS, [12] a 2.7–4% abso-
lute increase in overall survival (at 2 and 4 years), [11,12]
and can benefit many women in Ontario with this rela-
tively common condition. Although many of the drugs
listed in Table 1 were associated with smaller improve-
ments in patient outcome, the data in support of adjuvant
Table 1: Time to funding and episodes of media coverage for 18 anti-cancer agents and indications in Ontario as of August 1 2005.
Drugξ Indication Date Results 
Announced
Date Funded¥ Elapsed Number of 
Months€
Episodes of Media 
Coverage
Number Media 
Reports Per Month
Liposomal doxorubicin [14] Relapsed ovarian 21-05-00 01-10-01 16 0 0
Imatinib (PO) [15] Unresectable GIST 18-05-01 20-02-03 22 2 0.09
Zoledronic acid [16] Metastatic prostate 02-06-01 01-01-04 31 1 0.03
Zoledronic acid [17] Metastatic breast 21-10-01 Ongoing 46 1 0.02
Docetaxel [18] Neoadjuvant breast 10-12-01 01-08-04 32 3 0.09
Anastrazole (PO) [19] Adjuvant breast 10-12-01 22-02-05 39 33 0.85
Docetaxel [20] 1st line ovarian 18-05-02 Ongoing 38 1 0.03
Liposomal doxorubicin [21] Metastatic breast 18-05-02 Ongoing 38 1 0.03
TAC [22] Adjuvant breast 19-05-02 Ongoing 38 6 0.16
Premetrexed [23] Mesothelioma 20-05-02 Ongoing 38 7 0.18
Vinorelbine/trastuzumab [24] Metastatic breast 12-12-02 01-08-05 32 0 0
Letrozole (PO) [25] Adjuvant breast 05-12-03 Ongoing 20 16 0.8
Capecitabine (PO) [26] Adjuvant colon 06-06-04 Ongoing 16 0 0
Vinorelbine [27] Adjuvant NSCLC 06-06-04 01-08-05 14 17 1.21
Paclitaxel [28] Adjuvant NSCLC 06-06-04 Ongoing 14 3 0.21
Bortezomib [29] Relapsed myeloma 06-06-04 Ongoing 14 13 0.93
Docetaxel [30] Metastatic prostate 07-06-04 01-08-05 14 17 1.21
Trastuzumab [12–13] Adjuvant breast 16-05-05 01-08-05 3 51 17
ξDrugs are intravenous unless otherwise noted and are listed in chronologic order from date of results announced.
¥Data was censored at August 1st 2005. If no funding decision had been made by this date, time to funding was calculated using August 1st 2005 as the cut-off date.
€Rounded to the nearest month.BMC Cancer 2007, 7:110 http://www.biomedcentral.com/1471-2407/7/110
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chemotherapy for NSCLC were even more impressive
than those for trastuzumab. The JBR.10 study of adjuvant
vinorelbine/cisplatin for early-stage NSCLC demonstrated
an absolute improvement in 5 year survival of 15%.
Despite the impressive result of this Canadian-led study,
funding for adjuvant vinorelbine/cisplatin was not availa-
ble until 14 months after release of study results [27,36].
The relative cost of these agents also does not explain the
speed at which funding decisions were reached. Compar-
ing drug acquisition costs alone (figures in Canadian dol-
lars) a course of vinorelbine/cisplatin for resected NSCLC
($2 448) compares very favorably to a course of adjuvant
trastuzumab ($45 474) [37]. Furthermore, each of these
clinical conditions are common. In the coming year it is
estimated that approximately 370 patients in Ontario will
receive adjuvant vinorelbine/cisplatin for NSCLC and
approximately 1150 patients will receive a course of adju-
vant trastuzumab for breast cancer [38].
In the current study we have shown that there was consid-
erably more media coverage for trastuzumab than other
anti-cancer therapies. A recent report from the UK suggests
that intense media pressure influenced the decision to
fund adjuvant trasztuzumab [35]. The reasons for differ-
ential media interest are not clear but the contrast is most
striking when comparing adjuvant vinorelbine/cisplatin
for NSCLC to the trastuzumab experience. This phenom-
enon has been described in other reports in the literature.
In their review of health-related articles in Canadian
women's magazines, Hoffman-Goetz and MacDonald
found disproportionately fewer articles pertaining to lung
cancer than breast cancer relative to the mortality associ-
ated with each of these conditions [39]. In a separate
report, Otterson has proposed several hypotheses to
explain the lower public and media profile of lung cancer.
These include: the high mortality of lung cancer which
means there are fewer survivors and advocates to lobby on
its behalf; lack of prominent spokespeople highlighting
the illness; the perception that lung cancer is self-induced
by cigarette smoking; and finally the possibility that lung
cancer (and smoking) is associated with lower socio-eco-
nomic status [40]. In contrast, breast cancer has a very
large and well organized survivorship population with
Type and frequency of media reports between release of results and drug funding decision as of August 1, 2005 Figure 2
Type and frequency of media reports between release of results and drug funding decision as of August 1, 2005. Drugs are 
arranged along X-axis in increasing time to treatment funding decision.
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prominent spokespeople and may be seen as a disease
affecting otherwise healthy women.
Regardless of the reason for varying levels of media cover-
age for different anti-cancer drugs, the degree of media
attention may have a significant impact. In the recent
Cochrane overview it was reported that health-related
media coverage can induce important changes in the
delivery of health care [4]. The media clearly plays an
important role in the dissemination of health-related
information, however it is critical that health care provid-
ers and policy-makers recognize the possibility that these
reports may present a biased or incomplete picture of the
data and may exert undue influence on drug funding deci-
sions.
The current drug funding process in Ontario (CED-CCO)
appears (at least in certain instances) to have the ability to
generate funding decisions more quickly than its prede-
cessor. However, there are some limitations to this obser-
vation. The trastuzumab decision was released as part of a
"package" of funding decisions that represented the first
assessments made by the group (including vinorelbine for
the adjuvant treatment of lung cancer). It is possible that
some of the delay in the decision for vinorelbine for lung
cancer was due to the initiation of the new priority-setting
process. However, the lack of transparency in the current
CED-CCO decision-making process makes it difficult to
fully understand and appreciate how funding decisions
were made, why decisions took the time they did, and the
potential influence of external factors such as media atten-
tion. Furthermore, the closed decision-making process is
contrary to one of the basic tenets of the "legitimate and
fair process" described by Daniels [1]. In fact, within
Ontario there is currently a move towards a more trans-
parent process with the "Transparent Drug System for
Patients Act" that has recently been approved in the pro-
vincial legislature [41].
Although the difference in media attention and time to
funding between trastuzumab for breast cancer and other
anti-cancer agents is striking, this does not establish a
causal relationship. The rationing of medical resources is
a complex and multifactorial process that relies largely on
evidence of clinical benefit. However, this process is sub-
ject to external factors including the influence of media,
patient advocates, politicians, and industry. The data in
this case study serve to illustrate the significant involve-
ment one (or all) of these external factors may play in the
debate over priority-setting. An inherent limitation of this
Frequency of media reports for adjuvant trastuzumab Figure 3
Frequency of media reports for adjuvant trastuzumab.
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descriptive case study is that we are unable to quantify or
directly account for the influence of the media or any
other external factors. Nevertheless, while the speed of
decision for trastuzumab funding in Ontario is laudable,
to ensure that priority-setting for cancer therapies is a
legitimate and fair process, we must recognize the poten-
tial impact of external factors on decision-making and
ensure that all new and effective anti-cancer agents are
evaluated promptly and in a transparent manner.
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